Neuroendocrine Cells in Benign Prostatic Hyperplasia and Prostatic Carcinoma: Effect of Hormonal Treatment

1997 ◽  
Vol 59 (3) ◽  
pp. 149-153 ◽  
Author(s):  
José Luis Guate ◽  
Safwan Escaf ◽  
Carmen Luz Menendez ◽  
Miguel del Valle ◽  
José Antonio Vega
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Hormonal Treatment ◽  
Prostatic Hyperplasia ◽  
Neuroendocrine Cells

Prostatic Hexosaminidase Activity in Patients With Benign Prostatic Hyperplasia and Prostatic Carcinoma

1983 ◽  
Vol 130 (1) ◽  
pp. 193-193
Author(s):  
G.B. Whitehurst ◽  
J.P. Mashburn ◽  
T.G. Pretlow ◽  
E.L. Bradley ◽  
E.A. Boohaker
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Prostatic Hyperplasia

Characterization and Measurement of the Androgen Receptor in Human Benign Prostatic Hyperplasia and Prostatic Carcinoma

1977 ◽  
Vol 45 (5) ◽  
pp. 920-930 ◽  
Author(s):  
MAREK SNOCHOWSKI ◽  
ÅKE POUSETTE ◽  
PETER EKMAN ◽  
DOMINIQUE BRESSION ◽  
LENNART ANDERSSON ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Prostatic Hyperplasia

scholarly journals The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA

1999 ◽  
Vol 45 (11) ◽  
pp. 1960-1966 ◽  
Author(s):  
Angeliki Magklara ◽  
Andreas Scorilas ◽  
William J Catalona ◽  
Eleftherios P Diamandis
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Prostate Specific Antigen ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Prostatic Hyperplasia ◽  
Free Psa ◽  
Glandular Kallikrein ◽  
Total Psa

Abstract Background: Prostate-specific antigen (PSA) is the most reliable tumor marker available and is widely used for the diagnosis and management of prostate cancer. Unfortunately, PSA cannot distinguish efficiently between benign and malignant disease of the prostate, especially within the range of 4–10 μg/L. Among the refinements developed to enhance PSA specificity is the free/total PSA ratio, which is useful in discriminating between the two diseases within the diagnostic “gray zone”. Recent data indicate that human glandular kallikrein (hK2), a protein with high homology to PSA, may be an additional serum marker for the diagnosis and monitoring of prostate cancer. Methods: We analyzed 206 serum samples (all before treatment was initiated) from men with histologically confirmed benign prostatic hyperplasia (n = 100) or prostatic carcinoma (n = 106) with total PSA in the range of 2.5–10 μg/L. Total and free PSA and hK2 were measured with noncompetitive immunological procedures. Statistical analysis was performed to investigate the potential utility of the various markers or their combinations in discriminating between benign prostatic hyperplasia and prostatic carcinoma. Results: hK2 concentrations were not statistically different between the two groups of patients. There was a strong positive correlation between hK2 and free PSA in the whole patient population. hK2/free PSA ratio (area under the curve = 0.69) was stronger predictor of prostate cancer than the free/total PSA ratio (area under the curve = 0.64). At 95% specificity, the hK2/free PSA ratio identified 30% of patients with total PSA between 2.5–10 μg/L who had cancer. At 95% specificity, the hK2/free PSA ratio identified 25% of patients with total PSA between 2.5 and 4.5 μg/L who had cancer. Conclusions: Our data suggest that hK2 in combination with free and total PSA can enhance the biochemical detection of prostate cancer in patients with moderately increased total PSA concentrations. More specifically, the hK2/free PSA ratio appears to be valuable in identifying a subset of patients with total PSA between 2.5 and 4.5 μg/L who have high probability of cancer and who should be considered for biopsy.

Rapid radioimmunoassay for prostate-specific acid phosphatase in human serum.

1980 ◽  
Vol 26 (11) ◽  
pp. 1544-1547 ◽  
Author(s):  
P Vihko ◽  
A Kostama ◽  
O Jänne ◽  
E Sajanti ◽  
R Vihko
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Reference Group ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Serum Concentrations ◽  
Healthy Men ◽  
Monospecific Antisera ◽  
Group Serum

Abstract We describe a rapid radioimmunoassay for human prostatic acid phosphatase (EC 3.1.3.2) in serum, with use of monospecific antisera raised in rabbits against the primary highly purified acid phosphatase (pl 4.9) from human prostates, and with a second antibody-polyethylene glycol porecipitation. This radioimmunoassay is sensitive and can be performed within 5 h. Concentrations of the immunoreactive acid phosphatase in sera of healthy men (n = 394) ranged from 0.3 to 3.6 microgram/L (mean 1.94, SD 0.66 microgram/L). Concentrations of the enzyme in sera of men with benign prostatic hyperplasia (n = 56) or with carcinoma of nonprostatic origin (n = 24) were identical with those of the reference group. Serum concentrations of immunoreactive prostatic acid phosphatase of patients with occult, non-metastatic, and metastatic prostatic carcinoma varied from 1.7 to 9.3 (n = 9), 4.2 to 59.4 (n = 12), and 20 to 198 (n = 10) microgram/L, respectively. The amount of immunoassayable prostatic acid phosphatase was unchanged for at least five days in serum stored at 4 degrees C.

Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation.

Radiology ◽  
1989 ◽  
Vol 173 (3) ◽  
pp. 847-851 ◽  
Author(s):  
T Kahn ◽  
K Bürrig ◽  
B Schmitz-Dräger ◽  
J S Lewin ◽  
G Fürst ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Mr Imaging ◽  
Prostatic Carcinoma ◽  
Prostatic Hyperplasia
Sign in / Sign up

Export Citation Format

Share Document